嘉应制药：8月25日召开董事会会议

Group 1 - The core viewpoint of the article is that Jiaying Pharmaceutical announced the convening of its seventh board meeting to review the 2025 semi-annual report and its summary [1] - For the year 2024, Jiaying Pharmaceutical's revenue composition is 99.8% from the pharmaceutical industry and 0.2% from other businesses [1] - As of the report date, Jiaying Pharmaceutical has a market capitalization of 3.4 billion yuan [1]